NCOA3 and neoplasm: Therefore, SRC-3 inhibition with a low dose of SI-2 should increase immune cell proliferation and elevate the numbers of tumor-infiltrating T cells to generate an immunosuppressive microenvironment compared to that observed in response to vehicle treatment.